Aaron Cox - May 16, 2022 Form 3 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
May 16, 2022
Transactions value $
$0
Form type
3
Date filed
5/16/2022, 06:05 PM
Next filing
Dec 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HZNP Ordinary Shares 4.77K May 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HZNP Restricted Stock Units (RSU) May 16, 2022 Ordinary Shares 9.68K Direct F1
holding HZNP Restricted Stock Units (RSU) May 16, 2022 Ordinary Shares 18.6K Direct F2
holding HZNP Restricted Stock Units (RSU) May 16, 2022 Ordinary Shares 23.8K Direct F3
holding HZNP Performance Restricted Stock Units (PSU) May 16, 2022 Ordinary Shares 1.57K Direct F4
holding HZNP Performance Restricted Stock Units (PSU) May 16, 2022 Ordinary Shares 5.81K Direct F4
holding HZNP Performance Restricted Stock Units (PSU) May 16, 2022 Ordinary Shares 3.87K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The outstanding remaining shares vest on January 5, 2023.
F2 Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The outstanding remaining shares vest in equal installments on January 5, 2023 and January 5, 2024.
F3 Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. The 23,805 ordinary shares subject to the restricted stock units vest ratably over three years on each anniversary of the grant date (January 4, 2022).
F4 Each performance restricted stock unit represents a contingent right to receive one ordinary share of the Issuer subject to satisfaction of certain performance criteria. The outstanding remaining shares vest on January 5, 2023.